TEVA PHARMACEUTICAL-SP ADR(NYSE:TEVA) stock News

TEVA Latest News, Press Relases and Analysis

All

Press Releases

10 hours ago - By: Benzinga - Mentions: XBI IBB JAZZ SPRC ...

SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures

2 days ago - By: Zacks Investment Research - Mentions: SNY ALLO CMMB

TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder

3 days ago - By: The Motley Fool - Mentions: NVDA PLTR

Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026

5 days ago - By: Teva Pharmaceutical Industries Ltd

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

21 days ago - By: Benzinga

Is Teva Pharmaceutical Indus Gaining or Losing Market Support?

2 months ago - By: Stocktwits - Mentions: IYLD DFAX

This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More

5 days ago - By: Teva Pharmaceutical Industries Ltd

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

5 days ago - By: Zacks Investment Research - Mentions: JNJ AMGN KVUE

Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know

10 days ago - By: The Motley Fool - Mentions: PLTR NVDA TSM

Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters

13 days ago - By: Zacks Investment Research - Mentions: SNY FOLD

Can Galafold Drive Amicus' Growth Through the Rest of 2025?

15 days ago - By: Zacks Investment Research

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

15 days ago - By: Zacks Investment Research - Mentions: RDY ALVO

Here's How Alvotech is Expanding its Portfolio Beyond Immunology

20 days ago - By: Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

20 days ago - By: Teva Pharmaceutical Industries Ltd

Teva Releases Q3 2025 Aide Memoire

20 days ago - By: Teva Pharmaceutical Industries Ltd

Teva Releases Q3 2025 Aide Memoire

20 days ago - By: Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

25 days ago - By: Teva Pharmaceutical Industries Ltd

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

25 days ago - By: Teva Pharmaceutical Industries Ltd

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

25 days ago - By: Teva Pharmaceutical Industries Ltd

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

25 days ago - By: Teva Pharmaceutical Industries Ltd

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

a month ago - By: Yahoo Finance

Teva Pharmaceutical Industries Limited (TEVA)’s Emrusolmin Gains FDA Fast Track for Multiple System Atrophy

a month ago - By: Zacks Investment Research - Mentions: RDY ALVO

ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

a month ago - By: Zacks Investment Research - Mentions: SNY BMY NVO

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

2 months ago - By: Yahoo Finance

Teva Pharmaceutical Industries Limited (TEVA) Gains FDA Nod for Pediatric Migraine Drug AJOVY

2 months ago - By: Investor's Business Daily - Mentions: NVO

FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk

2 months ago - By: Teva Pharmaceutical Industries Ltd

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

2 months ago - By: Teva Pharmaceutical Industries Ltd

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

2 months ago - By: Yahoo Finance

Piper Sandler Reiterates a Buy Rating on Teva Pharmaceutical Industries (TEVA)

2 months ago - By: Zacks Investment Research - Mentions: JNJ AMGN KVUE

TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock News

TEVA Latest News, Press Relases and Analysis

SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures

TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder

Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Is Teva Pharmaceutical Indus Gaining or Losing Market Support?

This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know

Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters

Can Galafold Drive Amicus' Growth Through the Rest of 2025?

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

Here's How Alvotech is Expanding its Portfolio Beyond Immunology

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Teva Releases Q3 2025 Aide Memoire

Teva Releases Q3 2025 Aide Memoire

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Teva Pharmaceutical Industries Limited (TEVA)’s Emrusolmin Gains FDA Fast Track for Multiple System Atrophy

ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Teva Pharmaceutical Industries Limited (TEVA) Gains FDA Nod for Pediatric Migraine Drug AJOVY

FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

Piper Sandler Reiterates a Buy Rating on Teva Pharmaceutical Industries (TEVA)

J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?